ReviewSignal transduction therapy of cancer
Section snippets
Preface
In December 1971, when President Nixon signed the National Cancer Act, the United States started to fight cancer in an organized fashion. Since then, federal governments have invested more than 100 billion dollars in programs to fight, detect and prevent cancer. This act of the US government stimulated other non-profit organizations within the United States and worldwide to fund research on cancer. Many pharmaceutical companies have started to develop anti-cancer therapies, and today much of
General considerations
Cancer is a collection of over 100 diseases afflicting all body organs. Even a single type of cancer presents itself differently in different individuals. The disease is a malfunction of the biochemical networks and signaling networks that drive the normal cell. With time the cell accumulates mutations and epigenetic changes, which alter the signaling and biochemical networks. Certain combinations of these alterations lead to cell transformation and cancer.
The incidence of cancer is low but
Signal transduction as a platform for drug discovery
Signal transduction describes the conversion of external signals, generated by hormones, growth factors, neurotransmitters, chemokines, cytokines and even small molecules such as ATP, to a biochemical response, leading to a cellular response. These responses can lead to alterations in metabolism, gene expression, cell division, and cell death. The process can begin at the cell membrane or within the cell, leading to an array of biochemical reactions, depending on the signaling system. The
Target and drug evaluation using pre-clinical tumor models
The shift from cytotoxic chemotherapy to targeted signal transduction therapy necessitates a paradigm shift in the design of pre-clinical drug assessment strategies. In the quest for rationally developed drugs, target validation is a critical step towards verifying a purported mechanism of action. After a compound has been shown to inhibit the action of an oncoprotein such as a protein tyrosine kinase (PTK), one needs to find a cell line for which proliferation and/or survival depend on the
Protein kinase inhibitors
Protein phosphorylation is the most frequent post-translational modification of proteins and is intimately involved with many signal transduction processes. It is believed that at least one third of cellular proteins are phosphorylated and as a consequence they change their biochemical activities. Many of the 518 protein kinases are Ser/Thr kinases and only 91 are protein tyrosine kinases (PTKs). The 91 PTKs and a subset of Ser/Thr kinases are involved in cellular signaling. These signaling
Specific protein kinase targets and their targeting agents
In this section we shall focus on signaling pathways regulated by protein kinases. The signaling inhibitors discussed are mainly low molecular weight compounds and antibodies.
Targeting chaperone proteins: Hsp90 inhibitors
Chaperone proteins maintain the conformation, stability, activity and cellular localization of client proteins, many of which are involved in oncogenic signaling. Oncogenic proteins that require chaperones include c-Src, Bcr-Abl, Her2, C-Raf, B-Raf, CDK4, PKB/Akt, steroid hormone receptors, mutant p53, HIF1α, survivin and telomerase (hTERT). Because these oncogenic products require chaperone activity for correct folding and activity, the cancer cell is “addicted” to their chaperones, most
Proteasome inhibitors
Cancer cells are more sensitive than normal cells to proteasome inhibitors. This is probably because protein synthesis in cancer cells depends on the supply of amino acids generated by the degradation of proteins by the ubiquitin–proteasome system (Mizrachy-Schwartz and Levitzki, personal communication). Multiple myeloma (MM) cells show the highest sensitivity to proteasome inhibition. Proteasome inhibitors block IκB degradation and therefore attenuate NFκB signaling, on which MM cells depend
Targeting Bcl2 family proteins: BH3 mimetics
Bcl2 family proteins play a key role in the anti-apoptotic shield many leukemias and solid tumors develop. Bcl2 and its family members – BclXL, Bclw and Mcl-1– bind to the BH3 domains of pro-apoptotic proteins, thus preventing them from executing their pro-apoptotic activities. A number of agents that bind to the protein surfaces of the Bcl2 family proteins have been developed and shown to inhibit their anti-apoptotic effects. Thus, ABT 737 (Oltersdorf et al., 2005) was found to block Bcl2-
Targeting transcription as a therapeutic modality
Several of the best-selling therapeutic agents on the US market target transcription factors (TFs). All were discovered by targeting pathological phenotypes, and only later were they found to actually target TFs. Drugs that prevent transcription include: Cyclosporin A, an anti-inflammatory agent targeting nuclear factor of activated T cells (NF-AT); thiazolidinediones, which target Peroxisome Proliferator Activated Receptor γ (PPARγ) for the treatment of diabetes type 2 and the estrogen
Epigenetic therapy
The initiation and the progression of cancer are regulated by both genetic and epigenetic events. Epigenetic events, unlike genetic events, are in principle reversible. Epigenetic events include methylation and acetylation. Methylation occurs on DNA, modulating directly gene expression. Acetylation is well recognized on histones, modulating chromatin structure, also leading to modulation of gene expression. Acetylation can occur on many proteins that carry out vital functions within the cell.
Targeting angiogenesis
Solid tumors are composed of two interdependent compartments, the malignant cells and the tumor micro-environment, which includes the extracellular matrix, stromal cells and blood vessels. Inhibition of the stromal components that sustain the tumor is a valid strategy, if one can limit the toxic effects. One important target is angiogenesis, i.e. the formation of new blood vessels.
Immunotherapy of cancer
Cancer immunotherapy encompasses the use of specific antibodies against defined molecular targets, as well as recruitment and augmentation of the natural anti-tumor immune response. The aim of cancer immunotherapy is to harness the unique power of the immune system to hunt down cancer cells and destroy them.
DNA and RNA-based therapies
Gene therapy involves the use of nucleic acids for therapeutic purposes. The NIH registry of clinical trials (http://clinicaltrials.gov) lists more than 100 ongoing gene therapy trials for the treatment of cancer. Strategies for gene therapy for cancer include augmentation of tumor suppressors and inactivation of oncogenes. The major hurdle to effective gene therapy is delivery. Trials have been conducted mostly in cancers that tend to be localized and therefore lend themselves to local or
Resistance to therapy
We have outlined how signal transduction therapy is expected to have a major impact on cancer therapy. Nonetheless, serious problems remain, especially the development of resistance. As we have mentioned previously in this article, even tumors that are initially sensitive to a targeted therapy, generally develop resistance. This can be due to a mutation in the targeted molecule itself, as in the case of the so-called “gatekeeper” mutations in BCR-ABL that prevent Gleevec from binding. Analogous
Combination therapy
As discussed above, even tumors that are initially sensitive to a targeted therapy eventually become resistant, due to mutations in the target and/or due to bypass of the targeted pathway. “Smart cocktails” of therapeutic combinations are being designed, to reduce the probability of resistance emerging.
Synthetic lethality
The success of combination therapy is actually based on the cooperation of two (or more) gene products to assure cell survival. Whereas inhibiting the function of each gene product alone may have no effect or a weak effect, the inhibition of both induces lethality. These two genes are then considered to be “synthetically lethal” (Kaelin, 2005). Thus, if one knows the genetic lesions in a cancer cell one can, in principle, search for the genes within the cancer cells whose silencing will lead to
Conclusions
The last four decades following the 1971 anti-cancer act have seen tremendous progress in the war against cancer. Although the achievements in the clinic are not so dramatic so far, the path one needs to follow is becoming clearer. We all understand that for cancer therapy to succeed we need to develop biomarkers that will allow matching of the anti-cancer agents with the biochemical profile of the tumor. We also understand that we need to view the tumor as an organ in intimate interaction with
Levitzki has pioneered signal transduction therapy, especially in the field of tyrosine phosphorylation inhibitors (tyrphostins/TKIs). He was the first to design, synthesize and prove their efficacy in cells and in animal tumor models. His work led to the development of Gleevec, as Novartis’ CEO cites in “The Cancer Magic Bullet” (2003). Levitzki was the first to show that TKIs sensitize tumors to pro-apoptotic agents. He pioneered the Trojan horse approach to eradicate tumors overexpressing
References (167)
- et al.
Toxicogenomics of non-viral drug delivery systems for RNAi: potential impact on siRNA-mediated gene silencing activity and specificity
Adv. Drug Deliv. Rev.
(2007) - et al.
Selective interactions of transforming and normal abl proteins with ATP, tyrosine-copolymer substrates, and tyrphostins
J. Biol. Chem.
(1992) - et al.
Tyrphostin-induced inhibition of p210bcr-abl tyrosine kinase activity induces K562 to differentiate
Blood
(1993) - et al.
Activation of AKT kinases in cancer: implications for therapeutic targeting
Adv. Cancer Res.
(2005) - et al.
Lapatinib in breast cancer
Ann. Oncol.
(2007) - et al.
MT 110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors
Mol. Immunol.
(2006) Molecular mechanisms and therapeutic development of angiogenesis inhibitors
Adv. Cancer Res.
(2008)- et al.
PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment
Cancer Cell
(2009) Translation of the Philadelphia chromosome into therapy for CML
Blood
(2008)- et al.
Clonogenic assay with established human tumour xenografts: correlation of in vitro to in vivo activity as a basis for anticancer drug discovery
Eur. J. Cancer
(2004)
Novel actions of estrogen to promote proliferation: integration of cytoplasmic and nuclear pathways
Steroids
Prostate cancer gene therapy clinical trials
Mol. Ther.
The impact of mTOR inhibitors on the development of malignancy
Transplant. Proc.
Phosphatidylinositol ether lipid analogues that inhibit AKT also independently activate the stress kinase, p38alpha, through MKK3/6-independent and -dependent mechanisms
J. Biol. Chem.
The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors
Cancer Cell
Dual targeting of epigenetic therapy in cancer
Biochim. Biophys. Acta
p53 enters the microRNA world
Cancer Cell
Molecular imaging and therapy of cancer with radiolabeled nanoparticles
Nano Today
The role of KIT in the management of patients with gastrointestinal stromal tumors
Hum. Pathol.
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial
Lancet
Targeted cancer therapy: promise and reality
Adv. Cancer Res.
Targeting the EGFR and the PKB pathway in cancer
Curr. Opin. Cell Biol.
MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy
Blood
Checkpoint blockade in cancer immunotherapy
Adv. Immunol.
Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model
Cell
HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor
Mol. Cell
Shift from apoptotic to necrotic cell death during human papillomavirus-induced transformation of keratinocytes
J. Biol. Chem.
Epigenetics and cancer treatment
Eur. J. Pharmacol.
Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex
Cancer Cell
Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings
Adv. Drug Deliv. Rev.
Nonviral delivery of synthetic siRNAs in vivo
J. Clin. Invest.
Therapeutic window of MuS110, a single-chain antibody construct bispecific for murine EpCAM and murine CD3
Cancer Res.
Antitumor activity of an EpCAM/CD3-bispecific BiTE antibody during long-term treatment of mice in the absence of T-cell anergy and sustained cytokine release
J. Immunother.
Comparison of the EGFR resistance mutation profiles generated by EGFR-targeted tyrosine kinase inhibitors and the impact of drug combinations
Biochem. J.
Targeting Her-2/neu in breast cancer: as easy as this!
Oncology
The selectivity of protein kinase inhibitors: a further update
Biochem. J.
Tumor regression in cancer patients by very low doses of a T cell-engaging antibody
Science
Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors
Biochem. J.
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib
Proc. Natl. Acad. Sci. USA
Genetically engineered models have advantages over xenografts for preclinical studies
Cancer Res.
ROS, stress-activated kinases and stress signaling in cancer
EMBO Rep.
Designing transcription factor architectures for drug discovery
Mol. Pharmacol.
Inhibitors of chronically active ras: potential for treatment of human malignancies
Recent Pat. Anticancer Drug. Discov.
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck
N. Engl. J. Med.
Chemical inhibitors of protein kinases
Chem. Rev.
Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors
Cancer Res.
A transforming mutation in the pleckstrin homology domain of AKT 1 in cancer
Nature
Inhibition of Hedgehog signaling by direct binding of cyclopamine to smoothened
Genes Dev.
The type 1 insulin-like growth factor receptor pathway
Clin. Cancer Res.
EGFRvIII-targeted vaccination therapy of malignant glioma
Brain Pathol.
Cited by (0)
Levitzki has pioneered signal transduction therapy, especially in the field of tyrosine phosphorylation inhibitors (tyrphostins/TKIs). He was the first to design, synthesize and prove their efficacy in cells and in animal tumor models. His work led to the development of Gleevec, as Novartis’ CEO cites in “The Cancer Magic Bullet” (2003). Levitzki was the first to show that TKIs sensitize tumors to pro-apoptotic agents. He pioneered the Trojan horse approach to eradicate tumors overexpressing EGFR by targeting long chain dsRNA bound to a chemical vector guided by an EGFR ligand. This is developed as a platform for cancers overexpressing ligand induced internalizing receptors.
Klein obtained her Ph.D. degree from MIT in 1987, and then moved to Israel for postdoctoral studies with Giora Simchen. For the past 13 years, she has been a member of the Levitzki laboratory, where her interests include basic research into understanding oncogenesis and developing targeted therapies for cancer.